FYI-Expanding the presentation info:May 20th, 2025CHIASSO,...

FYI-Expanding the presentation info:
May 20th, 2025
CHIASSO, Switzerland and San Diego, US –May 20th, 2025 – Farma Mondo Group, a Swiss-based pharmaceutical group focused on providing market access and speciality distribution services through a unique infrastructure and geographical footprint across emerging and emerged markets, and Acadia Pharmaceuticals Inc. a biopharmaceutical company dedicated to developing and commercializing therapies that address unmet medical needs in central nervous system (CNS) disorders and rare diseases, have entered into an Exclusive Distribution Agreement to globally manage Named Patient Supply of DAYBUE® (trofinetide) in specific countries, primarily in Asia-Pacific (APAC-ex-Japan), South Asia, Latin Amecia (LATAM), the Middle East and North Africa (MENA), South Africa, Russia and the Commonwealth of Independent States (CIS). DAYBUE is the first and only FDA-approved treatment for Rett syndrome in adults and children 2 years of age and older.All requests will be managed through the dedicated email [email protected] Spigel, Group Chief Executive Officer of Farma Mondo, commented: We are honored to partner with Acadia Pharmaceuticals to help make DAYBUE available to patients and families around the world who are living with Rett Syndrome. I want to thank the Acadia Team for their trust and collaboration in this important initiative. This agreement significantly expands access to this first and only approved therapy in an area where there is significant unmet need. We look forward to leveraging our infrastructure on behalf to bring Acadia’s innovation to patients. Together, we win.
Kens